MétaCan
Menu
Back to cohort

A phase I/II study of TKM-080301, a <i>PLK1</i>-targeted RNAi in patients with adrenocortical cancer (ACC).

2016· article· en· W2481576503 on OpenAlexaff
Michael J. Demeure, Tannaz Armaghany, Samuel Ejadi, Ramesh K. Ramanathan, Aymen Elfiky, Jonathan Strosberg, David C. Smith, Timothy G. Whitsett, Winnie S. Liang, Shobana Sekar, John D. Carpten, Paul Fredlund, Demi Niforos, Andrew Dye, Sarabjit Gahir, Sean C. Semple, Mark Kowalski

Bibliographic record

VenueJournal of Clinical Oncology · 2016
Typearticle
Languageen
FieldMedicine
TopicAdrenal and Paraganglionic Tumors
Canadian institutionsArbutus Biopharma (Canada)
Fundersnot available
KeywordsMedicineMissense mutationCancer researchProgressive diseasePrimary tumorInternal medicineCancerPathologyMutationDiseaseGeneBiologyMetastasisGenetics

Abstract

fetched live from OpenAlex

2547 Background: Polo-like kinase 1 (PLK1) regulates critical aspects of tumor progression. High expression levels correlate with poor survival in ACC. TKM-080301 is a lipid nanoparticle formulation of a siRNA against PLK1. Methods: TKM-080301 was evaluated in an open-label study with dose escalation and expansion phases in patients with refractory ACC. TKM-080301 was infused IV over 30 minutes on days 1, 8, and 15 of a 28-day cycle. Primary study objectives included assessment of safety and anti-tumor activity by RECIST 1.1 after every 2 cycles. Results: Sixteen patients were treated at 0.6 or 0.75 mg/kg/week for up to 18 cycles. Eight received at least 2 cycles of study treatment and were evaluable for tumor response. Four had a best response of stable disease including one with a 13% reduction of target tumor diameter. One 51 yo man with metastatic intraperitoneal non-functional ACC had a partial response (target tumor reduction of 19% after cycle 2 and 49% after cycle 14). Residual tumor was resected and histopathology showed near-complete necrosis. Paired tumor/normal whole exome sequencing of this tumor revealed key somatic alterations including a missense mutation (Q331H) in TP53’s DNA binding domain, an NF1 nonsense mutation (S365*), and a missense ARID1A mutation (A438V). RNA sequencing showed elevated expression of PLK1 (FPKM = 13.5) in this tumor compared to a normal adrenal RNA control (FPKM = 0.95). Two subjects completed at least 6 cycles. Subjects were discontinued for progressive disease (7); infusion reactions (2); acute respiratory failure (1); elevated LFTs (1); or bowel obstruction (1). Most common AEs related to TKM-080301 were pyrexia (56%); chills (50%); back pain (31%); infusion reaction (31%); and nausea (25%). Serious AEs related to TKM-080301 were ECG T-wave inversion and musculoskeletal pain (1) and infusion reaction (1). Conclusions: TKM-080301 has been tolerated at a dose of 0.6 - 0.75 mg/kg for up to 18 cycles. Preliminary anti-tumor efficacy has been observed. A potential molecular therapeutic context of increased PLK1 expression with inactivation of p53 or NF1 was observed in a remarkable responder. Further evaluation of PLK1 as a therapeutic target of TKM-080301 in ACC is warranted. Clinical trial information: NCT01262235.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.000
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Non-randomized trial · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.002
Threshold uncertainty score0.008

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0010.000
Meta-epidemiology (narrow)0.0010.001
Meta-epidemiology (broad)0.0020.001
Bibliometrics0.0000.000
Science and technology studies0.0000.001
Scholarly communication0.0010.001
Open science0.0010.000
Research integrity0.0010.002
Insufficient payload (model declined to judge)0.0020.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.074
GPT teacher head0.460
Teacher spread0.386 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designNon-randomized trial
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations49
Published2016
Admission routes1
Has abstractyes

Explore more

Same venueJournal of Clinical OncologySame topicAdrenal and Paraganglionic TumorsFrench-language works237,207